Sign inJoin waitlistJoin the waitlist

Barbara Pro

Clinical Director of the Lymphoma Program · Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia

Credentials: · · · · ·

History

lymphoma program · Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia
Present
CUMC
Present

Research

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
Blood · 2022 · 1,363 citations
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study
Journal of Clinical Oncology · 2012 · First of 14 authors · Corresponding · 809 citations
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
The Lancet · 2019 · 613 citations

PM
Peter Mclaughlin
52 papers
Luis Fayad
50 papers
JR
Jorge Romaguera
45 papers
AY
Anas Younes
44 papers
Fredrick Hagemeister
37 papers
SH
Steven Horwitz
36 papers
Maria Rodriguez
34 papers
FS
Felipe Samaniego
32 papers
AS
Andrei Shustov
27 papers
MF
Michelle Fanale
25 papers
LK
Larry Kwak
23 papers
Ranjana Advani
23 papers

Clinical trials

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Principal investigator · Recruiting · Phase 1
SciTech Development, Inc.
2023–2027
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
Principal investigator · Unknown · Phase 1, Phase 2
Northwestern University
2015–2024
Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma
Principal investigator · Completed · Phase 2
Northwestern University
2015–2023
Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma
Principal investigator · Terminated · Phase 1
Northwestern University
2013–2016